<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<!DOCTYPE ichicsr SYSTEM "http://www.fda.gov/cder/aerssub/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
  <ichicsrmessageheader lang="en">
    <messagetype>ichicsr</messagetype>
    <messageformatversion>2.1</messageformatversion>
    <messageformatrelease>2.0</messageformatrelease>
    <messagenumb>CEL000000000001289018</messagenumb>
    <messagesenderidentifier>CELGENE</messagesenderidentifier>
    <messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
    <messagedateformat>204</messagedateformat>
    <messagedate>20130125101403</messagedate>
  </ichicsrmessageheader>
  <safetyreport lang="en">
    <safetyreportversion lang="en">0</safetyreportversion>
    <safetyreportid lang="en">US-CELGENEUS-163-21880-13013011</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20130125</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnesslifethreatening>1</seriousnesslifethreatening>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20130118</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20130118</receiptdate>
    <additionaldocument>2</additionaldocument>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb lang="en">US-CELGENEUS-163-21880-13013011</companynumb>
    <medicallyconfirm>1</medicallyconfirm>
    <linkedreport>
      <linkreportnumb>US-CELGENE-163-21880-08091561</linkreportnumb>
    </linkedreport>
    <linkedreport>
      <linkreportnumb>US-CELGENE-163-21880-09102348</linkreportnumb>
    </linkedreport>
    <primarysource>
      <reportergivename>Tom</reportergivename>
      <reporterfamilyname>Matthews</reporterfamilyname>
      <reporterstreet>Walgreens Specialty Pharmacy, 7164 Technology Drive, Suite 100</reporterstreet>
      <reportercity>Frisco</reportercity>
      <reporterstate>TX</reporterstate>
      <reporterpostcode>75034</reporterpostcode>
      <reportercountry>US</reportercountry>
      <qualification>2</qualification>
    </primarysource>
    <sender>
      <sendertype>1</sendertype>
      <senderorganization>CELGENEUS</senderorganization>
      <senderdepartment>Global Drug Safety</senderdepartment>
      <sendertitle>Manager</sendertitle>
      <sendergivename>Vivian</sendergivename>
      <senderfamilyname>Fonseca</senderfamilyname>
      <senderstreetaddress>300 Connell Drive, Suite 6000</senderstreetaddress>
      <sendercity>Berkeley Heights</sendercity>
      <senderstate>NJ</senderstate>
      <senderpostcode>07922</senderpostcode>
      <sendercountrycode>US</sendercountrycode>
      <sendertel>9082190331</sendertel>
      <senderfax>9086739115</senderfax>
      <senderemailaddress>vfonseca@celgene.com</senderemailaddress>
    </sender>
    <receiver>
      <receivertype>2</receivertype>
      <receiverorganization>FDAPM</receiverorganization>
      <receivergivename>Roger</receivergivename>
      <receivermiddlename>A</receivermiddlename>
      <receiverfamilyname>Goetsch</receiverfamilyname>
      <receivercountrycode>US</receivercountrycode>
    </receiver>
    <patient lang="en">
      <patientinitial>J-T</patientinitial>
      <patientbirthdateformat>102</patientbirthdateformat>
      <patientbirthdate>19460427</patientbirthdate>
      <patientsex>1</patientsex>
      <patientmedicalhistorytext lang="en">None Provided</patientmedicalhistorytext>
      <reaction>
        <primarysourcereaction lang="en">DISEASE PROGRESSION (MULTIPLE MYELOMA)</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10067095</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10028228</reactionmeddrapt>
        <termhighlighted>3</termhighlighted>
        <reactionstartdateformat>102</reactionstartdateformat>
        <reactionstartdate>20130114</reactionstartdate>
        <reactionfirsttime>9</reactionfirsttime>
        <reactionfirsttimeunit>802</reactionfirsttimeunit>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">FLU</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10016790</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10022000</reactionmeddrapt>
        <termhighlighted>1</termhighlighted>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>REVLIMID</medicinalproduct>
        <obtaindrugcountry>US</obtaindrugcountry>
        <drugauthorizationnumb>21-880</drugauthorizationnumb>
        <drugauthorizationcountry>US</drugauthorizationcountry>
        <drugauthorizationholder>Celgene Corporation</drugauthorizationholder>
        <drugstructuredosagenumb>25</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>21</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>21</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext lang="en">25 Milligram</drugdosagetext>
        <drugdosageform lang="en">Capsules</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10028228</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>201204</drugstartdate>
        <drugstartperiod>9</drugstartperiod>
        <drugstartperiodunit>802</drugstartperiodunit>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>20130114</drugenddate>
        <drugtreatmentduration>9</drugtreatmentduration>
        <drugtreatmentdurationunit>802</drugtreatmentdurationunit>
        <actiondrug>1</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <activesubstance>
          <activesubstancename>LENALIDOMIDE</activesubstancename>
        </activesubstance>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10067095</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10067095</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Not Related</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10016790</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not Provided</drugresult>
        </drugreactionrelatedness>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>FLUVIRIN</medicinalproduct>
        <obtaindrugcountry>US</obtaindrugcountry>
        <drugdosageform lang="en">Unknown</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10057097</drugindication>
        <activesubstance>
          <activesubstancename>INFLUENZA VIRUS VACCINE POLYVALENT</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>SYNTHROID</medicinalproduct>
        <obtaindrugcountry>US</obtaindrugcountry>
        <drugstructuredosagenumb>0.15</drugstructuredosagenumb>
        <drugstructuredosageunit>004</drugstructuredosageunit>
        <drugdosageform lang="en">Unknown</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10057097</drugindication>
        <activesubstance>
          <activesubstancename>LEVOTHYROXINE SODIUM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>LISINOPRIL</medicinalproduct>
        <obtaindrugcountry>US</obtaindrugcountry>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosageform lang="en">Unknown</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10057097</drugindication>
        <activesubstance>
          <activesubstancename>LISINOPRIL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>MS CONTIN</medicinalproduct>
        <obtaindrugcountry>US</obtaindrugcountry>
        <drugstructuredosagenumb>15</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosageform lang="en">Unknown</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10057097</drugindication>
        <activesubstance>
          <activesubstancename>MORPHINE SULFATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>WARFARIN</medicinalproduct>
        <obtaindrugcountry>US</obtaindrugcountry>
        <drugstructuredosagenumb>3</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosageform lang="en">Unknown</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10057097</drugindication>
        <activesubstance>
          <activesubstancename>WARFARIN</activesubstancename>
        </activesubstance>
      </drug>
      <summary lang="en">
        <narrativeincludeclinical lang="en">DISEASE PROGRESSION (MULTIPLE MYELOMA), FLU

(USA) Initial information was received on 18/Jan/2013 with subsequent information received on 21Jan2013 from a health care professional regarding a  66 year old male who received Revlimid 25 mg capsules orally daily for 21 days from /Apr/2012 to 14Jan2013 for the treatment of multiple myeloma. Lot number was A0177A and expiration date was 31/JAN/2015. Relevant medical history was not reported.  Concomitant medications included Fluvirin, Synthroid, Lisinopril, MS Contin, and Warfarin.
The patient experienced disease progression (multiple myeloma) on 14Jan2013 and was hospitalized.  The patient also experienced the flu (onset date not reported). The action taken with Revlimid for the flu was not provided. The action taken for disease progression (multiple myeloma) was therapy was permanently discontinued on 14Jan2013.
The patient will go into hospice care once released from the hospital.
The reporter deemed the event of disease progression (multiple myeloma) as life threatening.
The outcome of disease progression (multiple myeloma) was not recovered. The outcome of flu was unknown.
The reporter assessed the causal relationship for disease progression (multiple myeloma) as related to therapy.  The reporter did not provide a causality assessment for the event of flu and therapy.
Additional information will be requested from the prescriber.</narrativeincludeclinical>
        <sendercomment lang="en">A causal relationship between therapy and DISEASE PROGRESSION (MULTIPLE MYELOMA) is considered not related due to confounding by underlying disease.</sendercomment>
      </summary>
    </patient>
  </safetyreport>
</ichicsr>
